Citius Oncology Inc (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals Inc (Nasdaq: CTXR), announced on Friday that it has deployed an innovative AI platform to support its commercial team with advanced data analytics and insights ahead of the anticipated launch of LYMPHIR, a novel therapy for cutaneous T-cell lymphoma (CTCL).

This AI platform was developed to strengthen decision-making, refine targeting, and enhance the efficiency of its salesforce by supporting timely, data-informed engagement with healthcare providers.

The proprietary system uses company-defined criteria to identify patterns in treatment and diagnosis. The platform uses machine learning to continuously refine its ability to identify potential LYMPHIR candidates and allow the commercial team to support more informed patient care.

Designed as a continuous learning model, the AI platform adapts over time through ongoing integration of real-world U.S. claims data and marketing performance analytics.